1.
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
by Fellström, Bengt C, Prof
The Lancet (British edition), 2017, Vol.389 (10084), p.2117-2127
